BRAF and metastatic melanoma: A phase III clinical trial of vemurafenib compared to the standard therapy dacarbazine in previously untreated metastatic melanoma with known BRAF V600E mutation demonstrated an increase in overall survival of 20%, and a reduction of 63% in the risk of death in the vemurafenib group (75).